In 2021 we saw deals move away from the massive megamergers of 2019 to smaller collaboration and partnership agreements. In this article, European Pharmaceutical Review’s Hannah Balfour discusses the key deals of last year, whether the trend of high volume but small value will continue in 2022, and the motivations underpinning the recent changes in merger and acquisition (M&A) contracts with Subin Baral, EY Global Life Sciences Deals Leader.
“We never say never to mega deals – there is always potential for megamergers… But when we look at the trend, we expect volume: the collaboration activities, the partnership activities, the bolt-on acquisitions will be preferred in the coming years.” – Subin Baral, EY Global Life Sciences Deals Leader.
This webinar showcases the Growth Direct System; an RMM (Rapid Microbial Method) that improves on traditional membrane filtration, delivering increased accuracy, a faster time to result, enhanced data integrity compliance, and more control over the manufacturing process.
Key learning points:
Understand the benefits of full workflow microbiology quality control testing automation in radiopharmaceutical production
Learn about ITM’s implementation journey and considerations when evaluating the technology
Find out how the advanced optics and microcolony detection capabilities of Growth Direct® technology impact time to result (TTR).
Don’t miss your chance to learn from experts in the industry –Register for FREE
Can’t attend live? No worries – register to receive the recording post-event.
Through the last two years of the COVID-19 pandemic, a mainstay of the drug development community’s response has been collaboration. We have seen it in a variety of forms, including between Big Pharma and smaller companies, such as the Pfizer/BioNTech collaboration which led to the Comirnaty® messenger RNA (mRNA) vaccine for COVID-19, drug developers and regulators or government, increasing numbers of deals for outsourced development and manufacturing activities, and so on.
But will collaboration continue to be a critical paradigm for biopharmaceutical development?
A seller’s market
EY’s recent 2022 M&A Firepower report reveals that though the number of M&A deals that occurred during 2021 was greater than in previous years, the total value was the lowest since 2017.1 Overall, there were 90 M&As in 2021, a >20 percent increase in activity from the 70 and 69 that occurred in 2019 and 2020, respectively. However, their total value was $108 billion, a 60 percent decrease from the peak of $261 billion in 2019.
The existence of this valuation premium puts pressure on buyers to demonstrate quick returns on any acquisitions they make, acting as a deterrent to transactions”
This trend of increasing activity but decreasing value, which Baral expects will continue through 2022, is due to it being a seller’s market. He pointed to several factors promoting a shift in negotiation power away from Big Pharma companies towards smaller enterprises: “One is the patent cliff. All the big pharmaceutical companies are exposed to this cliff looming from 2025 onwards.” According to Baral, the internal pipelines of these large companies are not sufficient to overcome the growth gap potentially created by the fall in revenues after branded medications go off-patent, making them heavily reliant on external innovation.
However, it is often not as simple as directly acquiring companies and assets, because the valuations for these smaller companies are extremely high. Given the ample capital that is accessible for these smaller enterprises to enable their continued development, they are “not in a desperate mood to sell” explained Baral. He added: “The existence of this valuation premium puts pressure on buyers to demonstrate quick returns on any acquisitions they make, acting as a deterrent to transactions – and increasingly making partnerships and collaboration the preferred method.”
Does collaboration sound the death of the megamerger?
Baral cited one reason for the low total value of M&A deals in 2021 as the lack of megamergers. These are a subset of transformative M&A with valuations of at least $40 billion. The comparatively high value of 2019’s deals were driven by four megamergers totalling $231 billion, including Bristol Myers Squibb’s acquisition of Celgene ($74 billion) – the third largest in history, AbbVie/Allergan ($63 billion) and Takeda/Shire ($62 billion). Read our article to learn about the largest deals in 2019.
“The 60 percent fall from the 2019 peak is because people are skeptical, cautious about doing big deals and paying up front,” explained Baral, adding that, combined with the reluctance of smaller companies to sell, organisations are entering into collaborations or partnerships. These deals enable access to some assets, allow the larger companies to go in small, gain an understanding of the technology, people or market and then, if it seems promising, potentially acquire the company or asset.
An example of this is Pfizer’s investment in – and subsequent acquisition of – Trillium in 2021. Initially in 2020 Pfizer invested $25 million in Trillium, buying approximately 2.3 million of its common shares;2 then in 2021, Pfizer went on to acquire the company for a further implied equity value of $2.26 billion.3
“At EY, we never say never to mega deals – there is always potential for megamergers, especially if you look at companies with so much cash because of COVID-19 vaccines and so forth. These deals could happen. But when we look at the trend, we expect the volume; the collaboration activities, the partnership activities, the bolt-on acquisitions will be preferred in the coming years,” he added.
What were the largest deals of 2021?
CSL/Vifor – $11.7 billion4
In December, CSL announced it would acquire all publicly held Vifor Pharma shares in an all-cash public tender offer. The total aggregate equity value for Vifor was $11.7 billion.
The acquisition gave CSL access to Vifor’s portfolio of products across nephrology, dialysis and iron deficiency therapies, adding 10 commercialised products and 37 under development, increasing the company’s development pipeline by 37 percent.
Merck/Acceleron Pharma – $11.5 billion5
In September, Merck (MSD outside the US and Canada) and Acceleron Pharma announced their definitive agreement, whereby Merck, through a subsidiary, would acquire Acceleron for an approximate total equity value of $11.5 billion.
The acquisition complemented and strengthened Marck’s growing cardiovascular portfolio and pipeline, adding Acceleron’s lead therapeutic candidate, sotatercept for pulmonary arterial hypertension (PAH), as well as Reblozyl® (luspatercept-aamt), a first-in-class erythroid maturation recombinant fusion protein for the treatment of anaemia in certain rare blood disorders, to Merck’s portfolio.
Jazz Pharma/GW Pharma – $7.2 billion6
In February, Jazz Pharmaceuticals announced it would acquire GW Pharmaceuticals for $6.7 billion to cement its leadership in neuroscience and further diversify its portfolio.
The acquisition included GW’s lead product Epidiolex® (cannabidiol) oral solution, approved in patients one-year and older for the treatment of seizures associated with Lennox-Gastaut Syndrome (LGS), Dravet Syndrome and Tuberous Sclerosis Complex (TSC), as well as pipeline candidates such as nabiximols in Phase III development for spasticity associated with multiple sclerosis and spinal cord injury.
Pfizer/Arena Pharmaceuticals – $6.7 billion7
Pfizer revealed it would acquire all the outstanding shares of Arena Pharmaceuticals in an all-cash transaction of approximately $6.7 billion in December 2021.
This acquisition gave Pfizer access to Arena’s broad development pipeline of therapeutic candidates in gastroenterology, dermatology and cardiology; complementing the company’s inflammation and immunology pipeline with the addition of etrasimod, an oral, selective sphingosine 1-phosphate (S1P) receptor modulator currently in development for a range of immuno-inflammatory diseases including gastrointestinal and dermatological diseases.
Sparking innovation in more than therapeutics
As demonstrated above, the main impetus for M&A activity is the diversification and expansion of portfolios, according to Baral. He noted that these deals are occurring across a wide range of indications from oncology to immunology, neurology and more, but the key emerging areas are cell and gene therapy, mRNA, antibodies and protein degradation therapies. The first two are particularly key, according to Baral, who noted there has already been an uptick in interest and valuations for cell and gene therapies and mRNA. “These are platform based and people are really focused on how you can use that platform for not just one therapeutic area, but across many therapeutic areas and diseases,” he added.
deals are occurring across a wide range of indications from oncology to immunology, neurology and more, but the key emerging areas are cell and gene therapy, mRNA, antibodies and protein degradation therapies”
However, Baral explained that 2021 not only saw innovation in therapeutics, but also in M&A deal structures. For instance, MorphoSys’ acquisition of Constellation, a $1.7 billion deal financed by a long-term strategic funding partnership with Royalty Pharma plc.8 MorphoSys is a mid-sized biotech company that, through its partnership with Royalty, was able to finance a billion-plus dollar deal, which previously, according to Baral, seemed unlikely. Under the agreement, Royalty paid $1.425 billion upfront to MorphoSys to support the acquisition and will provide up to $350 million in Development Funding Bonds as well as $150 million in milestone payments in return for royalties on certain products.
M&A looking forward
Baral concluded that he anticipates 2022 will see very similar deals to 2021, with a lot of bolt-on acquisitions and a focus on collaborations and partnerships. “What is changing is there is ample capital in the market, so the power is shifting a little bit from Big Pharma to the mid-sized biopharma companies. They have a little more bargaining power now, with the innovation deficit and access to capital. Pharma companies are in desperate need to fill their pipelines for the looming patent cliff, so we expect a lot of deal making in 2022 and 2023. Now, they are not all going to be megamergers, but the valuations are high,” commented Baral.
This website uses cookies to enable, optimise and analyse site operations, as well as to provide personalised content and allow you to connect to social media. By clicking "I agree" you consent to the use of cookies for non-essential functions and the related processing of personal data. You can adjust your cookie and associated data processing preferences at any time via our "Cookie Settings". Please view our Cookie Policy to learn more about the use of cookies on our website.
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorised as ”Necessary” are stored on your browser as they are as essential for the working of basic functionalities of the website. For our other types of cookies “Advertising & Targeting”, “Analytics” and “Performance”, these help us analyse and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these different types of cookies. But opting out of some of these cookies may have an effect on your browsing experience. You can adjust the available sliders to ‘Enabled’ or ‘Disabled’, then click ‘Save and Accept’. View our Cookie Policy page.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Cookie
Description
cookielawinfo-checkbox-advertising-targeting
The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Advertising & Targeting".
cookielawinfo-checkbox-analytics
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Analytics".
cookielawinfo-checkbox-necessary
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Performance".
PHPSESSID
This cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy
The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
zmember_logged
This session cookie is served by our membership/subscription system and controls whether you are able to see content which is only available to logged in users.
Performance cookies are includes cookies that deliver enhanced functionalities of the website, such as caching. These cookies do not store any personal information.
Cookie
Description
cf_ob_info
This cookie is set by Cloudflare content delivery network and, in conjunction with the cookie 'cf_use_ob', is used to determine whether it should continue serving “Always Online” until the cookie expires.
cf_use_ob
This cookie is set by Cloudflare content delivery network and is used to determine whether it should continue serving “Always Online” until the cookie expires.
free_subscription_only
This session cookie is served by our membership/subscription system and controls which types of content you are able to access.
ls_smartpush
This cookie is set by Litespeed Server and allows the server to store settings to help improve performance of the site.
one_signal_sdk_db
This cookie is set by OneSignal push notifications and is used for storing user preferences in connection with their notification permission status.
YSC
This cookie is set by Youtube and is used to track the views of embedded videos.
Analytics cookies collect information about your use of the content, and in combination with previously collected information, are used to measure, understand, and report on your usage of this website.
Cookie
Description
bcookie
This cookie is set by LinkedIn. The purpose of the cookie is to enable LinkedIn functionalities on the page.
GPS
This cookie is set by YouTube and registers a unique ID for tracking users based on their geographical location
lang
This cookie is set by LinkedIn and is used to store the language preferences of a user to serve up content in that stored language the next time user visit the website.
lidc
This cookie is set by LinkedIn and used for routing.
lissc
This cookie is set by LinkedIn share Buttons and ad tags.
vuid
We embed videos from our official Vimeo channel. When you press play, Vimeo will drop third party cookies to enable the video to play and to see how long a viewer has watched the video. This cookie does not track individuals.
wow.anonymousId
This cookie is set by Spotler and tracks an anonymous visitor ID.
wow.schedule
This cookie is set by Spotler and enables it to track the Load Balance Session Queue.
wow.session
This cookie is set by Spotler to track the Internet Information Services (IIS) session state.
wow.utmvalues
This cookie is set by Spotler and stores the UTM values for the session. UTM values are specific text strings that are appended to URLs that allow Communigator to track the URLs and the UTM values when they get clicked on.
_ga
This cookie is set by Google Analytics and is used to calculate visitor, session, campaign data and keep track of site usage for the site's analytics report. It stores information anonymously and assign a randomly generated number to identify unique visitors.
_gat
This cookies is set by Google Universal Analytics to throttle the request rate to limit the collection of data on high traffic sites.
_gid
This cookie is set by Google Analytics and is used to store information of how visitors use a website and helps in creating an analytics report of how the website is doing. The data collected including the number visitors, the source where they have come from, and the pages visited in an anonymous form.
Advertising and targeting cookies help us provide our visitors with relevant ads and marketing campaigns.
Cookie
Description
advanced_ads_browser_width
This cookie is set by Advanced Ads and measures the browser width.
advanced_ads_page_impressions
This cookie is set by Advanced Ads and measures the number of previous page impressions.
advanced_ads_pro_server_info
This cookie is set by Advanced Ads and sets geo-location, user role and user capabilities. It is used by cache busting in Advanced Ads Pro when the appropriate visitor conditions are used.
advanced_ads_pro_visitor_referrer
This cookie is set by Advanced Ads and sets the referrer URL.
bscookie
This cookie is a browser ID cookie set by LinkedIn share Buttons and ad tags.
IDE
This cookie is set by Google DoubleClick and stores information about how the user uses the website and any other advertisement before visiting the website. This is used to present users with ads that are relevant to them according to the user profile.
li_sugr
This cookie is set by LinkedIn and is used for tracking.
UserMatchHistory
This cookie is set by Linkedin and is used to track visitors on multiple websites, in order to present relevant advertisement based on the visitor's preferences.
VISITOR_INFO1_LIVE
This cookie is set by YouTube. Used to track the information of the embedded YouTube videos on a website.